RCKT - イノテック・ファ―マシュ―ティカルズ （Rocket Pharmaceuticals Inc.）

As of Tuesday, Rocket Pharmaceuticals Inc.’s (NASDAQ:RCKT) stock closed at $19.21, up from $18.46 the previous day. While Rocket Pharmaceuticals Inc. has overperformed by 4.06%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, RCKT rose by 7.62%, with highs and lows ranging from $23.48 to $7.57, […]

Feb. 28 is Rare Disease Day . It''s meant to observe the more than 400 million people globally — 50% of them children — that are affected by rare, pediatric life-threatening diseases such as leukemia, Cystic Fibrosis and Hemophilia to name a few. But for Rocket Pharmaceuticals Inc. (NASDAQ: RCKT ), every day is rare disease day. The biotech firm, which went public in October, is among the most prominent players in the space with six genetic therapies in its pipeline. To learn more about the Cranbury, New Jersey-based company, Benzinga spoke with Rocket Pharma president and COO Kinnari Patel about the firm''s ongoing quest to find gene therapy cures. See Also: Rocket Pharmaceuticals Announces Proposed Public Offering Of $100M Of Shares Of Its Common Stock BZ: When Rare Disease Day was started in 2008, it was intended for Feb. 29 — a rare day that only occurs on leap years — by the European Organisation for Rare Diseases. Does the day get the attention it deserves in the U.S.? Patel : While Rare Disease Day has started to get attention in the U.S., it deserves even more attention, as the unmet needs for the global rare disease community are staggering.

Rocket Pharmaceuticals press release (RCKT): Q4 GAAP EPS of -$0.92 misses by $0.10.Cash, cash equivalents and investments of approximately $400M; expected operational runway through 2024

CRANBURY, N.J. (AP) — CRANBURY, N.J. (AP) — Rocket Pharmaceuticals Inc. (RCKT) on Monday reported a loss of $66.7 million…

CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare disorders with high unmet need, today reported financial and operational results for the fourth quarter and year ended December 31, 2022. “Rocket closed 2022 with positive results across four gene therapy programs spanning both our AAV cardiology and LV hematology therapeutic areas in an unpreceden

As of Tuesday, Rocket Pharmaceuticals Inc.’s (NASDAQ:RCKT) stock closed at $19.21, up from $18.46 the previous day. While Rocket Pharmaceuticals Inc. has overperformed by 4.06%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, RCKT rose by 7.62%, with highs and lows ranging from $23.48 to $7.57, […]

Feb. 28 is Rare Disease Day . It''s meant to observe the more than 400 million people globally — 50% of them children — that are affected by rare, pediatric life-threatening diseases such as leukemia, Cystic Fibrosis and Hemophilia to name a few. But for Rocket Pharmaceuticals Inc. (NASDAQ: RCKT ), every day is rare disease day. The biotech firm, which went public in October, is among the most prominent players in the space with six genetic therapies in its pipeline. To learn more about the Cranbury, New Jersey-based company, Benzinga spoke with Rocket Pharma president and COO Kinnari Patel about the firm''s ongoing quest to find gene therapy cures. See Also: Rocket Pharmaceuticals Announces Proposed Public Offering Of $100M Of Shares Of Its Common Stock BZ: When Rare Disease Day was started in 2008, it was intended for Feb. 29 — a rare day that only occurs on leap years — by the European Organisation for Rare Diseases. Does the day get the attention it deserves in the U.S.? Patel : While Rare Disease Day has started to get attention in the U.S., it deserves even more attention, as the unmet needs for the global rare disease community are staggering.

Rocket Pharmaceuticals press release (RCKT): Q4 GAAP EPS of -$0.92 misses by $0.10.Cash, cash equivalents and investments of approximately $400M; expected operational runway through 2024

CRANBURY, N.J. (AP) — CRANBURY, N.J. (AP) — Rocket Pharmaceuticals Inc. (RCKT) on Monday reported a loss of $66.7 million…

CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare disorders with high unmet need, today reported financial and operational results for the fourth quarter and year ended December 31, 2022. “Rocket closed 2022 with positive results across four gene therapy programs spanning both our AAV cardiology and LV hematology therapeutic areas in an unpreceden

A Rocket Pharmaceuticals, Inc. regulatory filing to the FDA of LV RP-L201 for Leukocyte Adhesion Deficiency-I is expected in the 1st half of 2023. Click to learn more.

Rocket Pharmaceuticals, Inc. , a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders with high unmet need,… | November 21, 2022

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic th

Shares of gene therapy concern Rocket Pharmaceuticals have fallen 75% from their all-time high set in February 2021 with the only setback a three-month hold on one clinical trial.